PD-1, CTLA-4 Point to Drug Response.
In a study of patients with metastatic melanoma, researchers reported that higher numbers of cytotoxic T cells positive for both PD-1 and CTLA-4 in the tumor predicted response to anti-PD-1 therapy and improved progression-free survival.